Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 72

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 72
---
. |

| (14) | Consists of 244,696 shares of common stock issuable upon exercise of options exercisable within 60 days of April 1, 2025. |

| (15) | Consists of 103,158 shares of common stock issuable upon exercise of options exercisable within 60 days of April 1, 2025. |

56

| (16) | Consists of 174,696 shares of common stock issuable upon exercise of options exercisable within 60 days of April 1, 2025. Dr. Pellini’s term as a Class III director is expiring at our 2025 Annual Meeting, and he is not being nominated for reelection. |

| (17) | Consists of (i) 3,394,922 shares of common stock held directly or indirectly by our directors and executive officers, (ii) 6,723,080 shares of common stock issuable upon exercise of options exercisable within 60 days of April 1, 2025 and (iii) 7,815 shares of common stock issuable upon issuance of a RSU award that vests within 60 days of April 1, 2025. |

OTHER MATTERS Delinquent Section 16(a) Reports Section 16(a) of the Exchange Act requires our executive officers, directors and persons who own more than ten percent of a registered class of our equity securities to file reports of ownership and changes in ownership with the SEC. Executive officers, directors and greater than ten-percentshareholders are required by SEC regulation to furnish us with copies of all Section 16(a) forms they file. Based solely on our review of the copies of such forms furnished to us and the written representations from certain of the reporting persons that no other reports were required during the year ended December 31, 2024, all executive officers, directors and greater than ten-percentbeneficial owners complied with the reporting requirements of Section 16(a). Shareholder Proposals and Nominations Shareholders who intend to have a proposal considered for inclusion in our proxy materials for presentation at our 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”) pursuant to Rule 14a-8under the Exchange Act must have submitted the proposal to our Corporate Secretary at our principal executive offices at 1165 Eastlake Avenue East, Seattle, Washington, 98109 not later than January 1, 2026. Shareholders intending to present a proposal at the